Business Wire

GLEIF Advances Digital Trust and Identity for Legal Entities Globally

10.12.2020 11:55:00 EET | Business Wire | Press release

Share

The Global Legal Entity Identifier Foundation (GLEIF) is to extend the Global LEI System to create a fully digitized LEI service capable of enabling instant and automated identity verification between counterparties operating across all industry sectors, globally.

Following a series of 2020 research initiatives, GLEIF today invites stakeholders from across the digital economy to engage in a cross industry development program to create an ecosystem and credential governance framework, together with a technical supporting infrastructure, for a verifiable LEI (vLEI), a digitally verifiable credential containing the Legal Entity Identifier (LEI).

By embedding new and existing LEIs in Verifiable Credentials1, the vLEI will create a cryptographically secure chain of trust that replaces today’s manual processes required to access and confirm an entity’s LEI data.

The vLEI will give government organizations, companies and other legal entities worldwide the capacity to use non-repudiable identification data pertaining to their legal status, ownership structure and authorized representatives in a growing number of digital business activities, such as approving business transactions and contracts, onboarding customers, transacting within import/export and supply chain business networks and submitting regulatory filings and reports.

“The global LEI system is unique in its capacity to provide regulated and standardized global identities for legal entities everywhere,” comments Stephan Wolf, CEO, GLEIF. “Our next step is to secure the process of presenting and verifying LEI data digitally, so it can be used across the digital economy in corporate ID use-cases. This year, GLEIF has begun exploring technical approaches across a number of industry sectors, with the aim of identifying an open and universally interoperable model. We’re excited to now formalize the vLEI development program and invite broader engagement to help us unlock the power of the LEI for all industry sectors around the world.”

Drummond Reed, Steering Committee Member, Trust-over-IP-Foundation, comments: “The vLEI has the potential to become one of the most valuable digital credentials in the world because it is the hallmark of authenticity for a legal entity of any kind. The family of digital credentials in the GLEIF vLEI Governance Framework can serve as a chain of trust for anyone needing to verify the legal identity of an organization or of a person legally acting on that organization’s behalf. The demand this will create for LEIs — and the impact it will have on adoption of self-sovereign identity — cannot be overestimated. It will be a sea change for digital trust infrastructure that will benefit every country, company, and citizen in the world.”

GLEIF is already engaged in research partnerships and technical trials with stakeholders in pharmaceutical, healthcare, telecom, automotive and financial services sectors. A range of blockchain, self-sovereign identity and other decentralized key management propositions are currently being explored.

Chris Ingrao, Chief Strategy Officer of Lumedic, a Tegria company, a US-based Health Information Logistics firm piloting the vLEI, comments: “Lumedic recently launched the Lumedic Exchange, the first healthcare ecosystem of its kind dedicated solely to community-driven standards development for patient-intermediated information exchange using verifiable credentials. It is attracting a multinational membership from a broad array of industries and needs to ensure all members are fully registered legal entities with strong accountability. The vLEI will enable us to standardize on a digital credential attesting to that status from all Lumedic Exchange members providing both efficiency and assurance.”

Steve Meizanis, Global Product Head of Symbology and LEI Services at Bloomberg LP, comments: “Bloomberg’s two vLEI proof-of-concept trials signal a clear opportunity to broaden the usage and increase adoption of the LEIs in digitized corporate activities. It also increases the scope for new and existing LEI issuers to offer vLEI services, strengthening the Global LEI System as a whole.”

GLEIF has collaborated with Deloitte to identify that demand generation for the vLEI will occur through a combination of existing LEI use-cases, including regulatory mandates for financial reporting, growth market segments in relation to new use-cases, such as Know Your Customer (KYC) procedures, and the broader digital economy, including strong anticipated growth in the area of self-sovereign Identity-enabled business ecosystems.

Derek Ryan, Partner, Deloitte, comments: “This is an exciting time for the self-sovereign identity industry. Universally trusted digital identities among both businesses and individuals are set to play a central role in our fast-evolving digital economy. Until now the absence of a trusted governance authority able to link digital identities with real world legal entities has presented an industry-wide barrier to innovation. GLEIF is very well positioned to overcome this barrier by extending the LEI as a critical component of the global digital economy. The potential value that will be unlocked by the vLEI is substantial, as it enables government authorities and identity service providers to embrace efficient new digital platforms, create new digital ecosystems and to end the reliance on repetitive manual identity verification steps which account for high annual costs across the global economy.”

-ENDS-

Additional GLEIF partner quotes supporting the vLEI

“The use of the LEI for fully distributed verifiable credentials provides a missing capability in distributed identity. The value extends far beyond financial services to e-commerce, trade services, and governmental reporting. The LEI in this way reinforces the value the ISO 17442 standard as the world of organizational identity in the digital world evolves.”

Jim Northey, Chair, ISO TC 68

“Obtaining a vLEI needs to be a core element to every company’s digital transformation strategy. This is especially true with any organization that works with financial and health data. Consumers and partners need to be able to trust and verify the identity of these organizations. We are committed to leveraging the combination of vLEIs, verified credentials standards, and cryptographic key management to drive broad scale adoption of digital identities, profiles, and the BurstIQ secure data network that was purpose built to exchange identity and health data.”

Frank Ricotta, CEO, BurstIQ

“Provenant is delighted to be working with GLEIF to help introduce verifiable Legal Entity Identifiers (vLEI) to the telecom industry. Telecom struggles to consistently identify originators of voice calls and messages, resulting in robocalls and spam. We believe GLEIF's effectiveness as a global root of trust for the financial sector could powerfully address cross-channel, cross-jurisdictional trust challenges faced by the telecom industry. We look forward to working with GLEIF to develop new solutions that utilize GLEIF and the vLEI to bring new levels of trust and verifiability to communications networks globally.”

Randy Warshaw, Founder, Provenant

Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images

Relevant link
https://www.gleif.org/en

1 ‘Verifiable Credential’ is defined by the Worldwide Web Consortium’s Verifiable Credentials Working Group here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elisabeth Dean, iseepr
elisabeth@iseepr.co.uk
+44 (0) 113 350 1922

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye